-
Diclofenac in Human Intestinal Organoid Assays
2026-08-12
Discover how Diclofenac can connect non-selective COX inhibition with human iPSC-derived intestinal organoid models. This article focuses on exposure design, epithelial pharmacokinetics, assay interpretation, and the limitations that determine whether organoid data translate to inflammation research.
-
D-N-Acetylgalactosamine: Protocol and QC Guide
2026-08-12
D-N-Acetylgalactosamine supports controlled studies of glycoprotein composition, brain heteropolysaccharides analysis, and glycosylation pathway workflows. It is suitable for aqueous or DMSO-based preparation, but not for ethanol-dependent protocols or long-term storage of prepared solutions.
-
Human Intestinal Organoids for Pharmacokinetic Studies
2026-08-11
Saito and colleagues established a direct three-dimensional cluster-culture strategy for generating human iPSC-derived intestinal organoids with long-term expansion, differentiation, and cryopreservation potential. The resulting organoid-derived epithelial cells contained mature intestinal cell types and enterocytes with cytochrome P450 and transporter activities, supporting more human-relevant pharmacokinetic studies than conventional models alone.
-
Epalrestat Workflow for Oxidative Stress Research
2026-08-11
Epalrestat connects polyol pathway inhibition with redox and mitochondrial assays, making it useful for diabetic neuropathy research and mechanistic Parkinson’s disease models. This guide translates recent KEAP1/Nrf2 findings into practical workflows, controls, and troubleshooting decisions for reproducible cell and animal studies.
-
2-Hydroxypropyl-β-cyclodextrin Protocol
2026-08-10
2-Hydroxypropyl-β-cyclodextrin (SKU B6413) is a cyclic oligosaccharide solubilizer for poorly water-soluble hydrophobic compounds, particularly molecules with aromatic or phenyl groups. This dossier-based guide supports formulation and biochemical solubility workflows, but does not establish compound-specific efficacy, pharmacokinetics, toxicity, or uses outside solubilization and excipient applications.
-
Dacomitinib (PF-00299804) Research Workflow
2026-08-09
Build a rigorous Dacomitinib workflow that connects irreversible pan-HER signaling blockade with receptor phosphorylation, cell-cycle, apoptosis, and mitochondrial stress readouts. The approach is especially useful for EGFR-mutant lung cancer models, resistant HER2-amplified systems, and carefully controlled exploratory studies of ferroptosis biology.
-
ECE-1c Stability, CK2, and Cisplatin Resistance
2026-08-08
Almarza et al. show that preventing Lys-6 ubiquitination stabilizes ECE-1c and promotes stemness, cisplatin resistance, and invasion in non-small cell lung cancer models. The findings connect CK2-dependent ECE-1c regulation with a non-canonical, endothelin-1-independent aggressive phenotype and provide a rationale for testing silmitasertib as a mechanistic CK2 probe.
-
Diclofenac: COX Inhibition in Organoid Research
2026-08-07
Diclofenac is a non-selective COX inhibitor used to investigate prostaglandin biology, inflammation signaling, and pain signaling research. Its defined physicochemical profile can support reproducible assays, while human pluripotent stem cell-derived intestinal organoids provide a complementary platform for pharmacokinetic studies.
-
Cyclophosphamide as an Alkylating Chemotherapeutic Agent: Wo
2026-08-07
Cyclophosphamide distinguishes itself as a DNA cross-linking cytotoxic compound and immunosuppressive agent, central to both apoptosis induction in cancer cells and bone marrow transplantation conditioning. This guide delivers actionable workflow optimizations, literature-backed protocol parameters, and troubleshooting strategies to maximize reproducibility and translational impact with APExBIO’s Cyclophosphamide.
-
Topotecan as a Novel Topoisomerase I Inhibitor in Cancer Tre
2026-08-06
This article reviews the pharmacological innovation and clinical experience with topotecan, a water-soluble camptothecin analogue that selectively inhibits topoisomerase I, inducing apoptosis in cancer cells. The findings highlight topotecan's unique mechanism, pharmacokinetics, and evidence-based efficacy in various solid tumors, providing critical insight for optimizing chemotherapeutic regimens and advancing cancer research.
-
Everolimus (RAD001): Applied mTOR Inhibition in Cancer Model
2026-08-06
Everolimus (RAD001) stands out as a robust, orally bioavailable mTOR inhibitor, enabling precise dissection of cancer cell proliferation and death in both in vitro and in vivo studies. This article details advanced workflows, troubleshooting strategies, and protocol optimizations for leveraging Everolimus in translational cancer research, grounded in the latest assay innovations.
-
3-Methyladenine for Autophagy Research: Practical Workflows
2026-08-05
3-Methyladenine (3-MA) is a gold-standard autophagy inhibitor, enabling precise dissection of PI3K-dependent pathways in cardiovascular, cancer, and metabolic research. This article translates breakthrough findings into actionable protocols, troubleshooting guidance, and comparative insights for advanced experimental design.
-
Cyclo (-RGDfC): Optimizing Integrin αvβ3 Targeting Workflows
2026-08-05
Cyclo (-RGDfC) empowers precise, high-throughput study of integrin-mediated cell adhesion and tumor targeting in advanced hydrogel and cellular assays. This guide unpacks practical integration, troubleshooting, and real-world protocol enhancements that leverage its unique cyclic structure and exceptional specificity.
-
Open-Platform DLP Enables High-Throughput Hydrogel Printing
2026-08-04
The referenced study introduces a low-cost, open-platform digital light printer (OP-DLP) for precise hydrogel fabrication and spatially controlled activation in 96-well formats. This innovation addresses reproducibility and scalability in biomaterials and cell-based research, with broad implications for high-throughput experimental design.
-
Amiloride (MK-870): Applied Workflows for Ion Channel Resear
2026-08-04
Amiloride (MK-870) stands as a gold-standard ENaC and uPAR inhibitor, powering robust sodium channel research, cellular endocytosis modulation, and disease modeling. This guide translates advanced mechanistic insights into workflow-ready protocols, troubleshooting strategies, and actionable enhancements for sodium channel and receptor pathway assays.